Ionis Pharmaceuticals IONS Debt conversion inducement expense
Debt conversion inducement expense at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InducedConversionOfConvertibleDebtExpense.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt conversion inducement expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt conversion inducement expense?
- Ionis Pharmaceuticals (IONS) reported debt conversion inducement expense of $4.09M in Q4 2025.
- What does debt conversion inducement expense mean?
- The cost of incentivizing debt holders to convert their debt into company stock.
- How do you interpret debt conversion inducement expense?
- An increase suggests active management of the balance sheet to reduce debt obligations, while a decrease indicates fewer conversion incentives were offered.
- How does debt conversion inducement expense compare across companies?
- Common in biotech and tech firms using convertible notes to manage capital structure; peers often report this as a non-cash financing adjustment.